Background: The urinary C-peptide/creatinine ratio (UCPCR) and fasting C-peptide level can assess beta-cell function in clinical practice. In the present study, the use of the UCPCR and fasting C-peptide levels was investigated in the differential diagnosis between maturity-onset diabetes of the young (MODY) and type 1 diabetes mellitus (T1DM). Methods: Twenty-seven patients with genetically confirmed MODY by next-generation sequence analysis and 42 children with T1DM were included. C-peptide levels were measured after an overnight fast before breakfast, and urine samples were collected 2 h after a standard lunch in the hospital. Results: The UCPCR in the T1DM group was 0.17 ± 0.5 nmol/mmol, and in the MODY group it was 1.27 ± 1.03 nmol/mmol (p = 0.001). The receiver operating characteristic (ROC) curves showed excellent discrimination (area under the curve 0.93). A UCPCR ≥0.22 nmol/mmol yielded a 96.3% sensitivity and an 85.7% specificity. The fasting C-peptide level in the T1DM group was lower than that in the MODY group (p = 0.001). The fasting C-peptide cutoff determined by ROC curve analysis was 0.62 ng/ml, with a sensitivity of 93% and a specificity of 90% for discriminating between MODY and T1DM. Conclusions: We showed that the UCPCR and fasting C-peptide levels in children and adolescents can distinguish patients with MODY from patients with T1DM with high specificity and sensitivity. A value of UCPCR ≥0.22 nmol/mmol may indicate further genetic testing for MODY.

Keywords:
Diabetes mellitus, Maturity-onset diabetes of the young, Urinary C-peptide
1.
Ledermann HM: Is maturity onset diabetes at young age (MODY) more common in Europe than previously assumed? Lancet 1995;345:648.
2.
Craig ME, Hattersley A, Donaghue KC: Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diabetes 2009;10(suppl 12):3-12.
3.
Karlsson E, Shaat N, Groop L: Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4A-MODY) and MODY 3 (HNF1A-MODY)? Diabet Med 2008;25:788-791.
4.
Cervin C, Axler O, Holmkvist J, Almgren P, Rantala E, Tuomi T, Groop L, Dahlbäck B, Karlsson E: An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA. J Intern Med 2010;267:316-321.
5.
Richter S, Shih DQ, Pearson ER, Wolfrum C, Fajans SS, Hattersley AT, Stoffel M: Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1α: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003;52:2989-2995.
6.
Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264.
7.
Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue K; International Society for Pediatric and Adolescent Diabetes: ISPAD Clinical Practice Consensus Guidelines 2006-2007. The diagnosis and management of monogenic diabetes in children. Pediatr Diabetes 2006;7:352-360.
8.
Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H; Type 1 Diabetes Trial Net Research Group, European C-Peptide Trial Study Group: Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-1971.
9.
Besser RE: Determination of C-peptide in children: when is it useful? Pediatr Endocrinol Rev 2013;10:494-502.
10.
Besser RE, Ludvigsson J, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT: Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care 2011;34:607-609.
11.
Besser RE, Shields BM, Casas R, Hattersley AT, Ludvigsson J: Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care 2013;36:195-201.
12.
Besser RE, Shields BM, Hammersley SE, Colclough K, McDonald TJ, Gray Z, Heywood JJ, Barrett TG, Hattersley AT: Home urine C-peptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes. Pediatr Diabetes 2013;14:181-188.
13.
Besser RE, Shepherd MH, McDonald TJ, Shields BM, Knight BA, Ellard S, Hattersley AT: Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-α/hepatocyte nuclear factor 4-α maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 2011;34:286-291.
14.
American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;34(suppl 1):S62-S69.
15.
Yılmaz Agladıoglu S, Aycan Z, Çetinkaya S, Baş VN, Onder A, Peltek Kendirci HN, Ceylaner S: Screening for mutations in Turkish children with a clinical diagnosis of maturity onset diabetes of youth (MODY). Pediatr Diabetes 2013;14(suppl 18):132.
16.
Ludvigsson J, Heding LG, Larsson Y, Leander E: C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control. Acta Paediatr Scand 1977;66:177-184.
17.
Steck AK, Winter WE: Review on monogenic diabetes. Curr Opin Endocrinol Diabetes Obes 2011;18:252-258.
18.
Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT: A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 2009;26:437-441.
19.
Fajans SS, Bell GI, Polonsky KS: Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001;345:971-980.
20.
Ludvigsson J, Carlsson A, Forsander G, Ivarsson S, Kockum I, Lernmark A, Lindblad B, Marcus C, Samuelsson U: C-peptide in the classification of diabetes in children and adolescents. Pediatr Diabetes 2012;13:45-50.
21.
Katz LE, Jawad AF, Ganesh J, Abraham M, Murphy K, Lipman TH: Fasting C-peptide and insulin-like growth factor-binding protein-1 levels help to distinguish childhood type 1 and type 2 diabetes at diagnosis. Pediatr Diabetes 2007;8:53-59.
22.
Tung YC, Lee JS, Tsai WY, Hsiao PH: Evaluation of beta cell function in diabetic Taiwanese children using a 6-min glucagon test. Eur J Pediatr 2008;167:801-805.
23.
Wang L, Lovejoy NF, Faustman DL: Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care 2012;35:465-470.
24.
Urbanová J, Rypáčková B, Kučera P, Anděl M, Heneberg P: Should the negativity for islet cell autoantibodies be used in a prescreening for genetic testing in maturity-onset diabetes of the young? The case of autoimmunity-associated destruction of pancreatic β-cells in a family of HNF1A-MODY subjects. Int Arch Allergy Immunol 2013;161:279-484.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.